Intravesical Oncolytic Immunotherapy Produces Complete Tumor Regression in Three-Quarters of Patients in Phase 3 Trial
For high-risk non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin therapy, cretostimogene produced durable remissions and the possibility of bladder preservation in a single-arm Phase 3 trial; however, without a randomized control group, its efficacy advantage still requires direct confirmation.